PBS Pacgen Life Science Corporation

Pacgen Life Science Corporation ("Pacgen") (TSX VENTURE:PBS) announced today
that Dr. Ming S. Liu has stepped down as Chief Executive Officer of the Company,
effectively immediately. The Company has appointed Mr. Chung-Yu Wang, current
Chairman and director of Pacgen, as its Interim Chief Executive Officer. 


Dr. Liu has elected to step down from his operational roles due to personal
reasons. He will continue to serve as a director of Pacgen. "On behalf of the
board of directors and Pacgen shareholders, we would like to extend our thanks
and gratitude to Dr. Liu for his hard work and effort devoted to Pacgen over the
past years," said Mr. Wang. 


About Pacgen

Pacgen is a life science technology company focused on the commercialization of
biomedical products and services, including its previous development of novel
therapeutic drug candidates. For additional information, please visit
www.pacgenlife.com.


Forward looking Statements

Certain statements included in this press release may be considered
forward-looking. Statements relating to, among other things, anticipated
financial performance, business prospects, strategies, regulatory developments,
market acceptance and future commitments constitute forward-looking statements.
All forward-looking statements are based on Pacgen's current beliefs and
expectations as well as assumptions relating to the successful completion of its
clinical trials and pre-clinical studies, the time and process required to
obtain regulatory approval for commercialization of its product, the ability of
Pacgen to raise additional capital in future on favourable terms, the impact of
competitive products and pricing in the market, new product development, and the
successful and timely completion of corporate collaborations or licensing
arrangements for its research programs. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual results,
level of activity, performance or achievements to be materially different from
those implied by such statements, and therefore these statements should not be
read as guarantees of future performance or results. Such factors include, among
others, our stage of development, lack of product revenues, additional capital
requirements, risk associated with completion of clinical trials and obtaining
regulatory approval, dependence on collaborative partners, and our ability to
protect our intellectual property. 


Wherever possible, words such as "anticipate", "believe", "expect", "may",
"could", "will", "potential", "intend", "estimate", "should", "plan", "predict",
"project" or the negative or other variations of such expressions reflect
Pacgen's current beliefs and assumptions and are based on the information
currently available to Pacgen. Certain risks and uncertainties, including those
risk factors identified by Pacgen in its annual management's discussion and
analysis dated July 30, 2012, may cause our actual results, level of activity,
performance or achievements to differ materially from those implied by forward
looking statements. Readers are cautioned not to place undue reliance on these
forward-looking statements, which are made only as of the date of this press
release. Pacgen disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law. For all forward-looking
statements, Pacgen claims the safe harbour for forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pacgen Life Sciences Corporation
Chung-Yu Wang
Chairman and Interim Chief Executive Officer
604-436-4388
604-436-4380 (FAX)
cy.wang@pacgenlife.com


Pacgen Life Sciences Corporation
Christina Yip
Chief Financial Officer and Secretary
604-436-4388
604-436-4380 (FAX)
Christina.yip@pacgenlife.com
www.pacgenlife.com

Pacgen Life Science (TSXV:PBS)
Historical Stock Chart
From Nov 2024 to Dec 2024

Pacgen Life Science (TSXV:PBS)
Historical Stock Chart
From Dec 2023 to Dec 2024